Genmab — September 2013
-
Matas har lige overhalt GEN i C20 stillingen - men der er stadig 2,5 måneder tilbage.
-
ja men de ligger da stadig indenfor 20?
-
absolut - det er kun fordi kirkbi handlede for 600 mio. Matas er ikke i nærheden af C20 baseret på daglig volumen
-
-
meget spændende slide, men holder den?
-
By filing for approval on the basis of compelling Phase 2 data, a breakthrough-designated product could potentially come to market approximately 3 years sooner than a drug without the breakthrough designation (Figure 2). - See more at: http://obroncology.com/obrgreen/article/FDAs-New-Breakthrough-Therapy-Designation#sthash.OqBLXcNr.dpuf
-
This year’s edition of the Bispecific Antibody Summit will be held September 24-26 in Boston, USA. Dr. Schuurman’s presentation, entitled Effective Tumor Killing by Bispecific IgG1-Her2XCD3 Antibodies Generated by Controlled Fab-Arm Exchange, is scheduled for 9.00 a.m. (EDT) on September 26.
-
mon ikke vi skal se godkendelser og reimbursement i denne prisklasse, før der kommer noget egentligt salg? Der skal bruges 29300 mg arzerra i et behandlingsforløb - og til en wholesalepris på ~usd 5,3, så løber det pænt meget op
-
sorry - usd 5,3 per mg
-
på den anden side - til den pris, så skal der ikke mange patienter til, før det virkelig brager igennem på omsætningen
-
Det er kr 850k per behandlingsforløb
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind